{"id":"tigit","name":"TIGIT","symbol":"TIGIT","route":"/targets/tigit/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26838","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181847","uniprot":"https://www.uniprot.org/uniprotkb/Q495A1/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q495A1","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4630878","open-targets":"https://platform.opentargets.org/target/ENSG00000181847","civic":"https://civicdb.org/genes/201633/summary","oncokb":"https://www.oncokb.org/gene/TIGIT","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TIGIT","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=TIGIT","depmap":"https://depmap.org/portal/gene/TIGIT?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000181847-TIGIT","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/201633","omim":"https://www.omim.org/entry/612859"}],"products":[{"id":"hb0036","name":"HB0036","status":"phase-2","modality":"bifunctional antibody (anti-PD-L1/anti-TIGIT, per the sponsor's description; form not stated in the registry record)","route":"/drugs/hb0036/"},{"id":"rilvegostomig","name":"Rilvegostomig","status":"phase-2","modality":"bispecific antibody","route":"/drugs/rilvegostomig/"},{"id":"tiragolumab","name":"Tiragolumab","status":"negative","modality":"Monoclonal antibody (anti-TIGIT)","route":"/drugs/tiragolumab/"}],"trials":[{"id":"nct04665856","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","nct":"NCT04665856","phase":"3","status":"completed"},{"id":"nct06868277","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","nct":"NCT06868277","phase":"3","status":"recruiting"},{"id":"nct06627647","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","nct":"NCT06627647","phase":"3","status":"recruiting"},{"id":"nct06692738","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","nct":"NCT06692738","phase":"3","status":"recruiting"},{"id":"nct06764875","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","nct":"NCT06764875","phase":"3","status":"recruiting"},{"id":"nct06564844","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","nct":"NCT06564844","phase":"3","status":"active"},{"id":"nct05904886","name":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell","nct":"NCT05904886","phase":"3","status":"active"},{"id":"nct07221253","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","nct":"NCT07221253","phase":"3","status":"recruiting"},{"id":"nct07720284","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","nct":"NCT07720284","phase":"3","status":"recruiting"},{"id":"nct06989112","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","nct":"NCT06989112","phase":"3","status":"recruiting"},{"id":"nct06467357","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","nct":"NCT06467357","phase":"3","status":"recruiting"},{"id":"nct06921785","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","nct":"NCT06921785","phase":"3","status":"recruiting"},{"id":"nct06357533","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","nct":"NCT06357533","phase":"3","status":"recruiting"},{"id":"nct06109779","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","nct":"NCT06109779","phase":"3","status":"active"},{"id":"nct07431281","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","nct":"NCT07431281","phase":"3","status":"recruiting"},{"id":"nct05645692","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","nct":"NCT05645692","phase":"2","status":"active"},{"id":"nct05009069","name":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","nct":"NCT05009069","phase":"2","status":"active"},{"id":"nct05805501","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","nct":"NCT05805501","phase":"2","status":"active"},{"id":"nct07069712","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","nct":"NCT07069712","phase":"2","status":"recruiting"},{"id":"nct07098338","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT07098338","phase":"2","status":"recruiting"},{"id":"nct05702229","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","nct":"NCT05702229","phase":"2","status":"recruiting"},{"id":"nct06342037","name":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","nct":"NCT06342037","phase":"2","status":"recruiting"},{"id":"nct05489211","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","nct":"NCT05489211","phase":"2","status":"recruiting"},{"id":"nct05775159","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","nct":"NCT05775159","phase":"2","status":"active"},{"id":"nct05123482","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","nct":"NCT05123482","phase":"1/2","status":"recruiting"},{"id":"nct06996782","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT06996782","phase":"1/2","status":"recruiting"},{"id":"nct04524871","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","nct":"NCT04524871","phase":"1/2","status":"active"},{"id":"nct05417321","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","nct":"NCT05417321","phase":"1/2","status":"recruiting"},{"id":"nct04995523","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","nct":"NCT04995523","phase":"1/2","status":"active"},{"id":"nct07115043","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","nct":"NCT07115043","phase":"1/2","status":"recruiting"}],"pathways":["nk-cell-recognition"],"companies":["astrazeneca","compugen","huabo-biopharm","roche-genentech"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"pd1-blockade","mechanism":"Alternative checkpoints (LAG-3, TIM-3, TIGIT)","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}